Methylation levels of cell-free DNA in pretreatment plasma samples from people with muscle-invasive bladder cancer may predict pathologic response to neoadjuvant chemotherapy, suggests an analysis of prospective SWOG S1314 data.

Individuals with urothelial bladder cancer have a distinct urinary volatile organic compound profile that could potentially be used as a biomarker for diagnosis and surveillance, UK research suggests.

medwireNews : A Clinical Practice Guideline for the management of bladder cancer has been developed by ESMO and published in the Annals of Oncology .

The PD-1 inhibitor pembrolizumab shows promising antitumor activity in people with BCG-unresponsive non-muscle-invasive bladder cancer with or without papillary tumors, show data from the phase 2 KEYNOTE-057 trial.

medwireNews : The US FDA has approved pembrolizumab for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guérin (BCG).

The adenovirus vector-based gene therapy nadofaragene firadenovec elicits durable responses in people with non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin, shows a phase 3 trial.

The National Comprehensive Cancer Network has issued patient-oriented guidelines to help individuals with bladder cancer better understand and manage their condition.

Thomas Flaig discusses the NCCN patient-oriented guidelines for bladder cancer, with a view to explaining the need for the guidance and what patients can hope to get from it.

Ultra-deep sequencing of circulating tumor DNA is highly sensitive and specific for early risk stratification in patients with bladder cancer, predicting treatment response and identifying patients with early metastatic relapse, indicate findings reported in the Journal of Clinical Oncology .

Neoadjuvant pembrolizumab therapy results in an “impressively high” pathologic complete response rate among patients with programmed cell death ligand 1-positive muscle-invasive bladder carcinoma, researchers say.

Neoadjuvant pembrolizumab therapy results in an “impressively high” pathologic complete response rate among patients with programmed cell death ligand 1-positive muscle-invasive bladder carcinoma, researchers say.

Patients with muscle-invasive bladder cancer who are current or former smokers are more likely to respond poorly to cisplatin-based neoadjuvant chemotherapy than their nonsmoking counterparts, researchers report in BJU International .

Neoadjuvant chemotherapy with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin achieves better outcomes than gemcitabine plus cisplatin or carboplatin in patients with muscle-invasive bladder cancer, research shows.

Compared with the general population, adults with a hospital-based diagnosis of hematuria have a long-term increased risk for cancer, particularly bladder and kidney cancers, according to a Danish study.

Click for details about the regulatory agency announcements on pembrolizumab and atezolizumab

Adjuvant chemotherapy plus radiotherapy significantly reduces locoregional recurrence compared with adjuvant chemotherapy alone in patients with locally advanced bladder cancer after radical cystectomy, phase II trial data show.